Peptide therapeutics: current status and future directions

被引:2593
作者
Fosgerau, Keld [1 ]
Hoffmann, Torsten [1 ]
机构
[1] Zealand Pharma AS, DK-2600 Copenhagen, Denmark
关键词
DELIVERY; AGONIST; GLP-1;
D O I
10.1016/j.drudis.2014.10.003
中图分类号
R9 [药学];
学科分类号
100702 [药剂学];
摘要
Peptides are recognized for being highly selective and efficacious and, at the same time, relatively safe and well tolerated. Consequently, there is an increased interest in peptides in pharmaceutical research and development (R&D), and approximately 140 peptide therapeutics are currently being evaluated in clinical trials. Given that the low-hanging fruits in the form of obvious peptide targets have already been picked, it has now become necessary to explore new routes beyond traditional peptide design. Examples of such approaches are multifunctional and cell penetrating peptides, as well as peptide drug conjugates. Here, we discuss the current status, strengths, and weaknesses of peptides as medicines and the emerging new opportunities in peptide drug design and development.
引用
收藏
页码:122 / 128
页数:7
相关论文
共 32 条
[11]
The Human Intestinal Microbiome: A New Frontier of Human Biology [J].
Hattori, Masahira ;
Taylor, Todd D. .
DNA RESEARCH, 2009, 16 (01) :1-12
[12]
Continuous subcutaneous delivery of exenatide via ITCA 650 leads to sustained glycemic control and weight loss for 48 weeks in metformin-treated subjects with type 2 diabetes [J].
Henry, Robert R. ;
Rosenstock, Julio ;
Logan, Douglas ;
Alessi, Thomas ;
Luskey, Kenneth ;
Baron, Michelle A. .
JOURNAL OF DIABETES AND ITS COMPLICATIONS, 2014, 28 (03) :393-398
[13]
Lactam bridge stabilization of alpha-helices: The role of hydrophobicity in controlling dimeric versus monomeric alpha-helices [J].
Houston, ME ;
Campbell, AP ;
Lix, B ;
Kay, CM ;
Sykes, BD ;
Hodges, RS .
BIOCHEMISTRY, 1996, 35 (31) :10041-10050
[14]
Just R, 2014, DIABETES, V63, pAl
[15]
Future directions for peptide therapeutics development [J].
Kaspar, Allan A. ;
Reichert, Janice M. .
DRUG DISCOVERY TODAY, 2013, 18 (17-18) :807-817
[16]
Liraglutide: the therapeutic promise from animal models [J].
Knudsen, L. B. .
INTERNATIONAL JOURNAL OF CLINICAL PRACTICE, 2010, 64 :4-11
[17]
Larsen B., Patent No. [US 6,528,48681, 6528486B1]
[18]
Larsen B, Patent No. [WO 99/ 46283, 9946283]
[19]
Stability of Protein Pharmaceuticals: An Update [J].
Manning, Mark Cornell ;
Chou, Danny K. ;
Murphy, Brian M. ;
Payne, Robert W. ;
Katayama, Derrick S. .
PHARMACEUTICAL RESEARCH, 2010, 27 (04) :544-575
[20]
Peptide-based radiopharmaceuticals and cytotoxic conjugates: Potential tools against cancer [J].
Okarvi, S. M. .
CANCER TREATMENT REVIEWS, 2008, 34 (01) :13-26